Kestra Medical Technologies, Ltd. priced its initial public offering at $23.00 a share, to list on the Nasdaq Global Select Market under the symbol KMTS. It filed a Form S-1 registration statement for an initial public offering on February 10, 2025. As of November 6, 2026, its final prospectus is on file (Form 424B4, December 3, 2025).
Sell to companies like Kestra Medical Technologies, Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Kestra Medical Technologies, Ltd. filed a Form S-1 registration statement for an initial public offering on 2025-02-10. It has amended it 2 times. It filed its final prospectus on 2025-12-03, at a public offering price of $23.00 per share. Each fact below is quoted from the filing named with it.
Also on the record for Kestra Medical Technologies, Ltd.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 8.5% of the class | 5%+ stakes | Source |
| April 8, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 10.2% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by T. Rowe Price Associates, Inc. | 7.5% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Bain Charger Holdings, L.P. | 43.1% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Endeavour Medtech Growth II LP | 4.2% of the class | 5%+ stakes | Source |
| October 7, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 10.2% of the class | 5%+ stakes | Source |
Check before you invest in Kestra Medical Technologies, Ltd.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Kestra Medical Technologies, Ltd. and the records around it.
Kestra Medical Technologies, Ltd. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Endeavour Medtech Growth II LP also filed stake reports on 1 other company: Rapid Micro Biosystems, Inc. (Feb 2026)
- T. Rowe Price Associates, Inc. also filed stake reports on 191 other companies: PACIFIC BIOSCIENCES OF CALIF (Nov 2026), APARTMENT INVT & MGMT CO -A (Oct 2026), BETA BIONICS INC (Oct 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Kestra Medical Technologies, Ltd.
Get an email when Kestra Medical Technologies, Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Kestra Medical Technologies, Ltd.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Kestra Medical Technologies, Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kestra Medical Technologies, Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
Our common shares are listed on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “KMTS.” On December 2, 2025, the last reported sale price of our common shares on Nasdaq was $23.01 per share.From the 424B4 filed 2025-12-03
Offering price
The as adjusted consolidated balance sheet data give further effect to our issuance and sale of 6,000,000 common shares in this offering at the public offering price of $23.00 per common share, after deducting underwriting discounts and commissions and estimated offering costs incurred by us.From the 424B4 filed 2025-12-03
Underwriters
Morgan Securities LLC and Goldman Sachs & Co. LLC are acting as representatives of the underwriters named below.From the 424B4 filed 2025-12-03
Use of proceeds
We intend to use the net proceeds from this offering, together with our existing cash, to scale up our commercial organization through the hiring of additional sales representatives, sales team leadership and clinical care specialists, as well as continued investments in our fleet of devices, supply chain and revenue cycle management capabilities.From the 424B4 filed 2025-12-03
Revenue
For the three months ended July 31, 2025, we generated revenue of $19.4 million, compared to revenue of $12.8 million for the three months ended July 31, 2024, representing 52.0% quarter-over-quarter growth.From the S-1 filed 2025-12-01
Net loss or income
We incurred net losses of $25.8 million and $20.3 million for the three months ended July 31, 2025 and 2024, respectively.From the S-1 filed 2025-12-01
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-02-10 | Registration statement filed | S-1 |
| 2025-02-26 | Registration statement amended | S-1/A |
| 2025-03-03 | Registration statement amended | S-1/A |
| 2025-03-06 | Final prospectus filed: the offering is priced | 424B4 |
| 2025-12-01 | Registration statement filed | S-1 |
| 2025-12-03 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Kestra Medical Technologies, Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.